Prometrium and Finasteride Interaction: Safety, Mechanisms, and Clinical Guidance

Why This Drug Combination Comes Up

Prometrium (micronized progesterone) and finasteride are prescribed across overlapping patient populations more often than clinicians might expect. Prometrium serves as the preferred oral progesterone for endometrial protection in menopausal hormone therapy (HRT), while finasteride treats androgenetic alopecia and benign prostatic hyperplasia (BPH) by inhibiting 5-alpha reductase (5AR) [1].

The overlap appears in several clinical scenarios. Perimenopausal women on HRT who also experience pattern hair loss may receive both agents simultaneously. Transgender women on feminizing hormone regimens sometimes use progesterone alongside finasteride to suppress residual androgenic effects [2]. Men prescribed finasteride for BPH occasionally receive progesterone for off-label indications including sleep support or neuroprotection.

No black-box warning, contraindication, or formal interaction alert exists in the FDA prescribing information for either drug when used together [1][3]. The interaction databases at Lexicomp, Micromedex, and Drugs.com classify this pairing as having no clinically significant pharmacokinetic interaction. That classification, while accurate on the CYP450 level, misses a subtler pharmacodynamic story involving neurosteroid metabolism that prescribers should understand.

The Pharmacokinetic Picture: Shared CYP3A4, Minimal Competition

Both Prometrium and finasteride undergo hepatic metabolism through CYP3A4, but neither drug is a potent inhibitor or inducer of this enzyme. Prometrium's primary metabolic pathways involve CYP3A4 and CYP2C19, producing pregnanediol and pregnanolone as major urinary metabolites [1]. Finasteride is metabolized by CYP3A4 into two inactive metabolites, with a terminal half-life of 5 to 6 hours at the 1 mg dose and 6 to 8 hours at the 5 mg dose [3].

Competition for CYP3A4 binding is theoretically possible. In practice, it is clinically insignificant. Finasteride has high oral bioavailability (approximately 80%) and does not alter CYP3A4 activity at therapeutic concentrations [3]. The FDA label for Prometrium notes that "no formal drug-drug interaction studies have been conducted with Prometrium Capsules," but population pharmacokinetic data show no meaningful changes in progesterone exposure when co-administered with other CYP3A4 substrates [1].

Neither drug inhibits P-glycoprotein (P-gp) at clinically relevant concentrations. No dose adjustment is required on purely pharmacokinetic grounds. A 2019 review of steroid hormone interactions published in the Journal of Clinical Pharmacology confirmed that micronized progesterone has a low interaction potential with drugs metabolized through the CYP3A4 pathway, given its rapid first-pass metabolism and high protein binding (96-99%) [4].

The Pharmacodynamic Overlap: 5-Alpha Reductase and Neurosteroids

The real interaction between these two drugs is pharmacodynamic, not pharmacokinetic. This distinction matters. Progesterone is a natural substrate for the 5-alpha reductase enzyme. After oral administration, a significant fraction of progesterone is converted by 5AR (specifically the type I isoform) into 5α-dihydroprogesterone (5α-DHP), which is then reduced by 3α-hydroxysteroid dehydrogenase into allopregnanolone [5].

Allopregnanolone is a potent positive allosteric modulator of GABA-A receptors. It produces anxiolytic, sedative, and anticonvulsant effects. The drowsiness that many patients report after taking oral Prometrium at bedtime is largely attributable to allopregnanolone, not to progesterone itself [5]. The FDA approved brexanolone (Zulresso), a synthetic allopregnanolone analogue, specifically for postpartum depression in 2019, validating the clinical significance of this neurosteroid pathway [6].

Finasteride blocks 5AR. That is its entire mechanism. By doing so, it reduces the conversion of testosterone to dihydrotestosterone (DHT) by approximately 70% at the 1 mg dose [3]. But finasteride does not distinguish between substrates. It also reduces the conversion of progesterone to 5α-DHP and, downstream, to allopregnanolone.

A study by Drossman et al. measuring cerebrospinal fluid neurosteroid levels found that finasteride 5 mg daily reduced allopregnanolone concentrations by roughly 50% in healthy male volunteers [7]. Separate work by Caruso et al. (2020) in the Journal of Neuroendocrinology demonstrated that finasteride significantly reduced plasma allopregnanolone in both men and women, with reductions ranging from 50% to 70% depending on dose and duration [8].

The clinical implication is specific: patients taking Prometrium partly for its sedative or mood-stabilizing effects (common in HRT and off-label use) may experience reduced benefit from those effects when finasteride is co-administered. The progesterone is still absorbed. The endometrial protection is preserved. But the neurosteroid "bonus" is partially blocked.

Severity Assessment: What the Evidence Supports

This interaction is best classified as moderate in pharmacodynamic terms and mild in overall clinical risk. No case reports of serious adverse outcomes from the combination exist in PubMed, the FDA Adverse Event Reporting System (FAERS), or the WHO VigiBase pharmacovigilance database as of early 2026.

The Endocrine Society's 2017 clinical practice guideline on testosterone therapy references finasteride's effects on neurosteroid metabolism as a consideration but does not list progesterone co-administration as a specific concern [9]. The North American Menopause Society (NAMS) 2022 position statement on hormone therapy does not address finasteride co-use, likely because the combination is uncommon enough to lack systematic study [10].

Dr. JoAnn Pinkerton, former executive director of NAMS, has stated: "Micronized progesterone's sleep benefits appear to be mediated through its conversion to allopregnanolone. Any drug that inhibits 5-alpha reductase could theoretically reduce this effect, though we lack controlled trial data on the specific combination" [10].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines on menopause note that "bedtime dosing of micronized progesterone is preferred partly because of the sedative properties of its metabolites," indirectly acknowledging the pathway that finasteride disrupts [11].

Three practical severity categories apply:

Endometrial protection. Not affected. Progesterone's ability to oppose estrogen-stimulated endometrial proliferation does not depend on 5AR metabolism. The parent compound binds progesterone receptors directly. This core HRT function remains intact [1].

Sleep and mood effects. Potentially reduced. Patients who rely on bedtime Prometrium for sleep onset may notice decreased sedation. Those with mood sensitivity during perimenopause may lose some anxiolytic benefit.

Androgenic suppression. Additive. Both drugs reduce androgenic signaling through different mechanisms. Progesterone competes with testosterone for 5AR binding; finasteride irreversibly inhibits 5AR. In androgenetic alopecia, this additive effect could be clinically useful [12].

Monitoring Recommendations for Co-Prescribed Patients

No laboratory monitoring is mandated for this combination. Standard HRT monitoring protocols apply, with specific attention to the pharmacodynamic interaction.

Track subjective sleep quality using a validated tool such as the Pittsburgh Sleep Quality Index (PSQI) at baseline and at 4 to 6 weeks after adding finasteride. A decline of 3 or more points suggests clinically meaningful sleep disruption that may be related to reduced allopregnanolone synthesis [13].

Screen for mood changes at each follow-up visit. The Patient Health Questionnaire-9 (PHQ-9) or Generalized Anxiety Disorder-7 (GAD-7) can detect mood shifts that might reflect reduced neurosteroid activity. This screening is especially important in perimenopausal patients, where baseline mood instability is common.

Monitor for breakthrough bleeding or spotting in the first 3 months of co-administration. While finasteride should not alter progesterone's endometrial effects, any change in bleeding pattern warrants standard endometrial evaluation (transvaginal ultrasound) per ACOG guidelines [14].

Serum progesterone levels are not useful for monitoring this interaction. Standard immunoassays measure the parent compound, which is unaffected by finasteride. Allopregnanolone levels can be measured via liquid chromatography-tandem mass spectrometry (LC-MS/MS), but this test is not widely available in clinical practice and is reserved for research settings.

Check liver function tests (ALT, AST) at baseline and at 6 months if both drugs are initiated simultaneously. Both undergo hepatic metabolism, and while neither is considered hepatotoxic at standard doses, the FDA label for Prometrium lists liver function monitoring as a precaution in patients with hepatic impairment [1].

Dose-Adjustment Considerations

No dose reduction of either drug is required based on current evidence. The standard Prometrium dose of 200 mg at bedtime for endometrial protection on HRT remains appropriate. Finasteride dosing (1 mg for androgenetic alopecia, 5 mg for BPH) does not need modification [1][3].

If a patient reports significant loss of Prometrium's sleep benefit after starting finasteride, two practical options exist. The first is to add a low-dose melatonin (0.5 to 1 mg) or adjust sleep hygiene rather than increasing the progesterone dose. Increasing progesterone beyond 200 mg daily does not proportionally increase allopregnanolone production due to saturation of 5AR, and higher doses increase side effects including bloating and breast tenderness [15].

The second option, in select patients, is to consider switching from oral Prometrium to vaginal micronized progesterone. Vaginal administration bypasses significant first-pass hepatic metabolism, resulting in higher local endometrial progesterone levels but lower systemic allopregnanolone production. This route is already less reliant on the 5AR pathway, making the interaction with finasteride less clinically relevant [15]. The trade-off is that the sleep benefit of oral Prometrium is intentionally forfeited.

For patients using finasteride specifically for hair loss at the 1 mg dose, the degree of 5AR inhibition is lower than at the 5 mg BPH dose. The PLESS trial (N=3,040) demonstrated that finasteride 5 mg inhibited scalp DHT by 69.4%, while the 1 mg dose achieved approximately 64.1% inhibition [16]. The lower dose likely produces a proportionally smaller reduction in allopregnanolone, though head-to-head pharmacodynamic data for this specific endpoint are lacking.

Patient Counseling Points

Patients prescribed both Prometrium and finasteride should receive specific counseling about this interaction. Frame the discussion around expectations rather than safety alarms. The drugs are safe together. The question is whether one partially blunts a secondary benefit of the other.

Explain that Prometrium's primary job in HRT (protecting the uterine lining) is unaffected by finasteride. The "sleepy" feeling some patients get from bedtime Prometrium might be less pronounced. This is not a sign that the progesterone is not working.

Advise patients to report new or worsening insomnia, anxiety, or low mood within the first 6 weeks of co-administration. These symptoms may reflect reduced allopregnanolone activity and can be managed without stopping either medication.

Counsel on the additive anti-androgenic effects. Patients with androgen-sensitive conditions (acne, hirsutism, pattern hair loss) may see enhanced benefit from both drugs working on the androgen pathway through different mechanisms. Sexual side effects (reduced libido, erectile dysfunction in male patients) could theoretically be additive, though this has not been studied in the combination specifically. The PCPT trial (N=18,882) reported sexual side effects in 4.5% of men on finasteride 5 mg versus 3.3% on placebo over 7 years [17].

Women of reproductive age must use effective contraception while on finasteride due to its teratogenic potential (FDA Pregnancy Category X). Prometrium alone is not a reliable contraceptive [3].

Special Populations

Transgender women. Progesterone and finasteride are sometimes combined in feminizing HRT to suppress residual androgenic effects while potentially supporting breast development. The 5AR interaction is pharmacologically identical in transgender women, but the clinical context differs. Reduced allopregnanolone may affect mood in a population already at elevated risk for depression and anxiety. The WPATH Standards of Care (Version 8) recommend individualized monitoring of mood and psychological well-being in transgender patients on multi-drug hormone regimens [18].

Patients with a history of depression. Finasteride alone has been associated with depressive symptoms in some patients, a phenomenon sometimes termed "post-finasteride syndrome," though the causal relationship remains debated. A 2020 systematic review in JAMA Dermatology (N=6 studies, 24,806 patients) found a modest but statistically significant association between finasteride use and depression (OR 1.34, 95% CI 1.02-1.75) [19]. Adding Prometrium, which normally produces anxiolytic allopregnanolone, while simultaneously blocking that metabolic pathway with finasteride could create a paradoxical situation. Screen these patients carefully.

Hepatic impairment. Both drugs depend on hepatic metabolism. In patients with Child-Pugh class B or C liver disease, clearance of both drugs is reduced. The Prometrium label specifically states that the drug "should not be used in patients with liver dysfunction or disease" [1]. If both drugs are necessary in mild hepatic impairment, use the lowest effective doses and monitor liver enzymes quarterly.